The mid-autumn disclosure cycle for Chinese robotics and medical device developers highlighted new public market listings, cross-border regulatory clearances, and updated operational footprints across commercial and clinical environments. On the capital markets front, YOGO Robot confirmed the completion of its initial public offering on the Hong Kong Stock Exchange. In overseas regulatory affairs, SURGLASSES secured 510(k) clearance from the United States Food and Drug Administration (FDA) for its orthopedic planning software. Simultaneously, interim financial filings and operational updates from Yunji Technology, RainMed Medical, and TrueHealth provided concrete figures on organizational headcounts, active fleet utilization, and hospital procurement progress.
These disclosures offer an empirical look at the varied operational scales across service, interventional, and surgical robotics companies.
Yunji Technology: Fleet Expansion and Operational Growth
Interim reporting and autumn business updates from Yunji Technology illustrate an expanding operational scale across commercial hospitality and healthcare delivery. In its 2026 interim report published on 24 September 2026, the company disclosed that it had 321 employees, including executive directors, as of 30 June 2026. This represents an increase compared to the 253 employees reported as of 30 June 2025, although it remains below the site’s previously listed figure of more than 500 employees. Between mid-2025 and mid-2026, the group expanded its overall workforce by roughly 27%.
The group’s operational metrics show concurrent expansion in device deployment and active network utilization. In the first half of 2026, Yunji Technology maintained an average of approximately 36,000 daily online robots, representing year-on-year growth of 30%, according to the company’s interim report. In a separate business update released on 16 October 2026, the company reported that its cumulative product coverage had surpassed 45,000 hotels.
Alongside its established hotel footprint, the company detailed direct progress within healthcare logistics. In the same 16 October 2026 update, Yunji Technology disclosed an order from ecosystem partner Runyi involving 100 robots, which have begun deployment across multiple hospitals. This hospital deployment marks an extension of the company’s dispatch and mobile technology into institutional medical facilities.
YOGO Robot Formalizes Hong Kong Main Board Listing
Capital market access remains a primary objective for commercial service robotics developers, as evidenced by YOGO Robot’s recent stock exchange disclosures. In a monthly return of equity issuer securities submitted to the Hong Kong Stock Exchange on 2 October 2026, the company disclosed that its H shares had officially listed on the Main Board on 9 September 2026 under stock code 03231.
The regulatory filing confirmed the commencement of public trading for the robotics developer following its listing process. While the monthly return did not provide specific operational metrics or commercial installation figures, it formalizes YOGO Robot’s transition to a publicly traded issuer in Hong Kong.
Commercial Penetration and Headcount at RainMed Medical
RainMed Medical’s 2026 interim report, published on 25 September 2026, provided insight into the commercial reach of its clinical systems as well as its organizational size. As of 30 June 2026, the company employed 208 full-time personnel, with the majority based in China.
The interim report disclosed extensive installation and evaluation figures for its core medical systems. As of 30 June 2026, RainMed Medical had cumulatively sold and installed its core products in more than 790 hospitals. In addition, more than 1,500 hospitals in China had used the company’s core products, and the group had completed procurement approval procedures in over 750 hospitals across the country.
The clinical adoption numbers highlight a substantial gap between procedural evaluations and finalized commercial sales. The total pool of hospitals that have used the group’s core devices (over 1,500 institutions) is roughly double the number of hospitals where systems have been permanently sold and installed (over 790 institutions). Meanwhile, the tally of institutions that have completed procurement approval (over 750) aligns closely with the total installed base, indicating that procurement clearance remains an essential gating factor before a trial converts into an installation.
TrueHealth Discloses Mainland-Concentrated Staffing Base
In its 2026 interim report published on 14 September 2026, TrueHealth disclosed its organizational staffing footprint as of the end of the first half. The group reported a total of 158 full-time employees as of 30 June 2026.
The disclosure detailed the geographic concentration of TrueHealth’s personnel. Out of the 158 full-time employees, 150 were based in the Chinese mainland, meaning mainland operations account for roughly 95% of the company’s aggregate workforce. This staffing distribution indicates that the company’s product development, administration, and commercial activities remain overwhelmingly concentrated in domestic centers.
SURGLASSES Secures US FDA 510(k) Clearance for OOOPDS Software
Beyond mainland capital and operational filings, cross-border regulatory clearances advanced for regional orthopedic developers. On 15 September 2026, Taiwan Main Orthopaedic Biotechnology Co., Ltd. (SURGLASSES) received 510(k) premarket clearance from the US FDA for its medical image processing and surgical planning software, OOOPDS.
The regulatory clearance was issued under 510(k) document number K254214. By securing marketing authorization for OOOPDS, the company obtained regulatory entry for its digital surgical planning software into the US clinical market, establishing an official compliance foundation for its software solutions overseas.
Patterns & Outlook
The disclosures across September and October 2026 illustrate contrasting organizational profiles and expansion strategies between service robotics developers and specialized clinical device makers.
First, staffing profiles reflect the structural differences between software, interventional hardware, and high-volume delivery robotics. While Yunji Technology expanded its workforce from 253 to 321 employees between June 2025 and June 2026 to support active fleets of tens of thousands of units, specialized clinical developers TrueHealth and RainMed Medical reported leaner organizations of 158 and 208 full-time employees, respectively. TrueHealth’s heavy mainland concentration (150 of 158 staff) indicates that specialized developers continue to operate with focused domestic teams.
Second, hospital penetration pathways are evolving differently across sectors. For RainMed Medical, expanding deep within clinical institutions involves managing a multi-stage funnel: over 1,500 hospitals have trialed products, over 750 have cleared procurement procedures, and over 790 have received sold installations. In contrast, service robotics developers like Yunji Technology are entering hospital logistics through partner orders, deploying batches of 100 units alongside broader consumer-facing deployments across more than 45,000 hotels.
Finally, capital and regulatory milestones remain bifurcated between Hong Kong equity markets and overseas regulatory authorities. YOGO Robot’s H-share listing on 9 September 2026 confirms continued use of the Hong Kong Main Board for institutional capitalization, while SURGLASSES’s 510(k) clearance for OOOPDS illustrates ongoing efforts by regional developers to validate planning systems in the North American market. Tracking whether these trial numbers and clearances translate into expanded commercial revenue will be the key focus in upcoming reporting periods.